Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: GSK’s Stealth Move To The Coasts

Executive Summary

The British pharma opens new innovation centers in San Diego and Cambridge, Mass., to connect with those academic, business and venture investment communities. Also, Roche and Biogen Idec make moves in neurodegenerative disease, Retrophin makes two deals for different forms of the same drug, and GSK makes the latest alliance in the cancer immunology arena.

You may also be interested in...



Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

GSK Ventures Into The Device World Through Bioelectronic Investment

The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.

Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up

The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel